Last time I posted about CAPRICOR, it was at $5.50/share, now trading at $19. It has a 50% haircut from it's ATH from the last short-squeeze in November upon positive readout.
Here we are again, sure, a higher entry point, but even more upside in less than 30 days. $CAPR is about to have its final FDA meetings heading into the August 22 FDA approval date.
Short interest has climbed all the way back to 30% from where it was in November before the Shorts got crushed.
They just signed a long-term lease for a major $180 million structure to handle manufacturing inhouse fully vertically integrated. At this point, all signs point to success, and the readout of results cannot be forgotten, meeting both primary endpoints.
I have bought 250,000 shares heading into the August dates, as not only do I believe it is a strongly undervalued stock, I believe upon approval it will be acquired by a larger player who wants to add their platform to expand drug use cases and application. Add in the 30% short interest, it can be a ticking timebomb to the upside.
There's plenty more technical medical data to support the thesis, but the high-level is undervalued due to short-sellers re-entering the field with uneducated articles for a second time.
Price Target: $52-55/share post readout, higher short-term based on short-squeeze
Risk: Non-Approval and longer timeline to approval from ADCOMM.